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ABSTRACT 
Objective: The objective of the present study is to prepare a better form of paclitaxel cocrystal with improved solubility. Paclitaxel (PTX) is a class-4 
drug; this drug has low aqueous solubility and high affinity for P-gp. Available formulation are IV based and using our research work with 
advantages of co-crystal technology towards the enhancement of paclitaxel solubility and thereby its bioavailability (1) and also to improve the 
patient compliance.  
Methods: Naringen was selected based on their chemical nature and its ability to inhibit P-gp, solvent assisted grinding method used to prepare the 
cocrystals, and prepared cocrystals were subjected to solid state characterization to determine the crystal structure of the cocrystals, as this can 
provide significant new insights into how the drug and coformer interact, and thereby provide an excellent crystal engineering guide to new 
cocrystals, potentially with improved properties. Instruments like Fourier transform infrared spectroscopy(FTIR), differential scanning calorimetry, 
X-ray powder diffraction will be used to determine their stability and any phase transformations (including decomposition) which they might 
undergo as a function of temperature.  
Results: Principle involved in the formation of cocrystal is hydrogen bonding between C=O and N-H group of drug and COOH groups of coformers, 
which is confirmed by FTIR data and DSC experiments were carried out to study the melting point and heat of enthalpy of the cocrystals. Results 
clearly shows that the melting point of the cocrystals was increased which confirms the formation of cocrystals. The drug and formation of 
cocrystals are explained by the X-ray powder diffraction patterns. The PXRD patterns of the pure drug showed sharp, well-defined peaks(spectrum 
attached) and cocrystals PXRD patterns shows that there is a significant difference in the entire diffraction pattern, changes in peak locations with 
respect to pure drug indicates a change in the arrangement of molecules, hence confirms the development of new crystalline phase. 
Conclusion: The results obtained from the above experiments clearly shows the formation of cocrystals with improved solubility. 
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INTRODUCTION 
In the pharmaceutical industry, less than 1% of pharmaceutically 
active compounds eventually appear in the marketplace mainly due 
to its poor biopharmaceutical properties rather than toxicity or lack 
of efficacy. The solubility remains the key issue among these 
biopharmaceutical properties. According to recent studies, 75% of 
the drug development candidates had low solubility and belonged to 
biopharmaceutical classification system (BCS) classes II and IV.  
Many approaches like micronisation, salt formation, emulsification, 
solubilisations using co-solvents, use of polymer drug vehicles for 
delivery of poorly soluble drugs, reduction in the particle size (nano–
drug delivery) have been used to improve the aqueous solubility of 
drugs. Although these techniques have been shown to be effective at 
enhancing oral bioavailability, the success of these approaches is 
dependent on the specific physicochemical nature of the molecules 
being studied. Over the last decade, design of pharmaceutical 
cocrystals emerged as an important method for improving the 
bioavailability of drugs with low aqueous solubility [1]. 
Cocrystals are structurally homogeneous crystalline materials 
containing two or more components (generally referred to as drug and 
coformer) indefinite stoichiometric amounts [1]. Cocrystals are 
different from other multicomponent crystals such as hydrates or salts 
in a manner that drug and coformer are solids at ambient temperature 
and that the intermolecular interactions are non-ionic in nature [2]. 
Pharmaceutically pertinent properties that can be affected by 
cocrystallization include but are not limited to solubility, dissolution, 
moisture uptake, chemical stability, mechanical properties, and 
bioavailability. Of these properties, solubility is the most widely 
appreciated in the literature [2]. 
Paclitaxel is a drug of choice in the treatment of breast cancer, it has 
a bioavailability at less than 10% because of limited aqueous 
solubility, also affinity towards CYP metabolic enzymes and the P-
glycoprotein [4]. Many attempts were made to improve the oral 
bioavailability of paclitaxel-like selective modulation of P-
glycoprotein, self-emulsifying drug delivery systems and paclitaxel-
loaded lipid nanocapsules [5]. Cocrystals technique can be used as 
one of the technique because of it commercial feasibility and also for 
increase the diversity of solid-state forms of a drug even for non-
ionizable drugs, and enhance pharmaceutical properties by 
modification of chemical stability, moisture uptake, mechanical 
behaviour, solubility, dissolution rate, and bioavailability [6, 7]. 
Oral treatment with anticancer agents is, if feasible, to be preferred, as 
this route of administration is convenient to patients, reduces 
administration costs and facilitates the use of more chronic treatment 
regimens. There are some efforts for enhancing the oral bioavailability 
of paclitaxel by d-alpha-tocopheryl polyethylene glycol 400 succinate 
in mice and results indicated that TPGS 400 enhances the oral 
bioavailability of paclitaxel in mice and the enhancement may result 
from an increase in intestinal absorption of paclitaxel [8]. 
Paclitaxel cocrystals were prepared using solvent assisted co-
grinding and co-grinding method and with the help of solid-state 
characterization, paclitaxel with tartaric acid, succinic acid and 
nicotinamide in the molar ratios of 1:1 using co-grinding method 
was confirmed the formation of cocrystals [9]. 
Naringin is one of the widely available natural flavonoids; it inhibits 
cytochrome enzymes. So we have selected naringin as one of the 
coformer because it has two major advantages as coformer i.e. it 
inhibits cytochrome enzymes so we can prevent the metabolism of 
paclitaxel by using this flavonoid and also it easily forms cocrystal 
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with paclitaxel based on the structural configuration so we can 
expect improvement in the solubility as well as bioavailability of the 
paclitaxel cocrystals. Using naringin as coformer we are going to 
develop paclitaxel cocrystals with enhanced solubility while 
maintaining or improving other relevant physical properties 
(stability, processability, etc.). and always oral treatment with 
anticancer agents is, if feasible, to be preferred, as this route of 
administration is convenient to patients, reduces administration 
costs and facilitates the use of more chronic treatment regimens. 
  
 
Fig. 1: Chemical structure of Paclitaxel 
 
 
Fig. 2: Chemical structure of Naringin 
 
MATERIALS AND METHODS 
Materials 
Drug: Paclitaxel as gift sample from Cipla, Mumbai and Intas, 
Mumbai. 
Coforms: Naringin from sigma Aldrich. 
Acetonitrile (HPLC grade) and Triethylamine: Merck Life Sciences 
Private Limited, Mumbai. 
Orthophosphoric acid: Nice chemicals, Mumbai. 
Instruments used: High performance liquid chromatography (HPLC) 
from Shimadzu LC-10 series chromatographic system, Shimadzu 
Corporation, Kyoto, Japan., Differential Scanning calorimeter (DSC) 
from Shimadzu, DSC-60, Japan., Fourier transform infrared 
spectroscopy (FTIR) from Shimadzu FTIR-8300 system, Kyoto, 
Japan., Powder X-ray diffractometer (PXRD) from Rigaku mini flex 
600, Rigaku Co., Tokyo, Japan., Incubator shaker from Labtop 
Instruments Pvt. Ltd, Maharashtra, India. 
Methods 
Selection of coformers 
The selection of relevant cocrystal former becomes a crucial issue 
and requires creating supramolecular libraries of crystallizing 
agents. Analysis of existing crystal structures represents the first 
step in a crystal engineering experiment and thereby collecting the 
information concerning common functional groups and how they 
engage in the molecular association. Carboxylic acid moieties 
represent one of the most commonly studied functional groups in 
crystal engineering These are excellent starting point for crystal 
engineering of pharmaceutical co-crystals and the complementary 
hydrogen bond donor, and acceptor sites make them more favorable 
coformers, but the selection of coformers not limited to carboxylic 
acids, the alcohol amine, alcohol pyridine supramolecular hetero 
synthons are also well established in crystal engineering.  
Coformer with higher solubility tends to increase cocrystal solubility 
effectively, hence selection of conformer plays a crucial role.  
A search of the cambridge structural database will be employed to 
identify likely hydrogen-bonding motifs for paclitaxel. Synthesis of 
new co-crystal materials will be guided by the outputs of this work. 
Naringin was selected as the coformer because of its various 
advantages listed in the introduction. 
Preparation of cocrystals of paclitaxel: naringin  
Different Mole ratios of paclitaxel and naringin were weighed 
separately mainly 1:1, 1:2, 2:1 molar ratios. Different ratios of the 
drug and the individual coformers were subjected to optimized 
solvent assisted solid state grinding method and triturated at a 
constant speed without producing heat for about 30 min using a 
granite mortar and pestle [7, 11]. The resulting powder mixture was 
collected, stored for analysis. The batches with the mole ratios are 
mentioned in table 1. The powder samples were then collected for 
further (PXRD, FTIR and DSC) analysis. 
 
Table 1: Batches of paclitaxel cocrystals prepared using co-grinding method 
S. No. Co-crystal batch code Co former used Technique used Ratio 
1.  CCN-1 Naringin Solvent assisted Co-grinding 1:1 
2.  CCN-2 Naringin Solvent assisted Co-grinding 1:2 
3.  CCN-3 Naringin Solvent assisted Co-grinding 2:1 
 
Stability studies 
Drug content determination of cocrystals and chemical stability 
Chemical stability was carried out by dissolving a known amount of 
sample in the mobile phase and injected the sample to HPLC equipped 
with photodiode array detector. The total peak purity was calculated for 
the sample peak to confirm that no coelution from the degradants to the 
peak of interest with the help three-dimensional assessment of the 
chromatogram with the help of LC solution software and drug content 
was calculated with reference to initial assay value. 
Physical stability 
Optimized CCN-1 batch was stored under dry conditions in 
desiccators (dry condition was achieved by using CaCO3 crystals at 
the bottom of the desiccator) at 25 ° and 40 °C for up to 30 d and 
further extended up to 90 d. The samples were analyzed by XRPD.  
Solubility studies of prepared cocrystals 
To evaluate the enhancement of solubility of a crystalline form, it is 
important to investigate the saturation solubility. Equilibrium 
solubility of paclitaxel cocrystal shall be determined at room 
temperature by shake flask method over 72 h. 
An excess amount of pure, physical mixture and cocrystals of 
Paclitaxel were added separately to ultra-clear water and phosphate 
buffer pH 6.8. Then the mixture was kept in an orbital shaker (100 
agitations/min) for 72 h at room temperature.  
The samples were filtered through a 0.45 µm membrane filter 
(Millex-HA filter units, Millipore) and suitably diluted with diluent 
before analysis. The samples were analyzed by HPLC method as 
described below. The experiments were conducted in triplicates 
(n=3).  
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Analytical techniques 
HPLC analysis for saturation solubility and drug content 
determination and chemical stability  
The analysis was carried out on a shimadzu LC-10 series 
chromatographic system (Shimadzu Corporation, Kyoto, Japan). 
More precisely, the system consisted of a model SCL-10A 
controller unit, a model DGU-2A degasser unit, an LC-20AD 
quaternary gradient pump, SIL10AD refrigerated autosampler and 
a Model SPD-M10AVP PDA detector. System control, data 
acquisition and processing were performed with a PC-Pentium IV 
Processor personal computer operated with Microsoft windows 7 
and shimadzu LC solution 1.24 SP1 software. Standard substances 
were weighed on AY 220 shimadzu analytical balance. A glass 
vacuum filtration apparatus (Alltech Associates) was employed for 
the filtration of buffer solution using 0. 45 um filter obtained from 
Pall Life Sciences. Degassing of the mobile phase was performed 
by sonication in oscar micro clean-103 ultrasonic bath. The drug 
was successfully eluted on an HIBAR C18 (250 × 4.6 mm i.d., 5µ) 
column, in 70:30 ratio of acetonitrile and water (mixed with 
1%v/v triethylamine; pH adjusted to 4.50±0.05 with 10%v/v 
orthophosphoric acid) as the mobile phase. The PDA detector set 
at 227 nm was used to monitor the paclitaxel peak.  
DSC studies 
Differential scanning calorimetry was performed using DSC-60, 
shimadzu japan, the instrument comprised of the calorimeter, flow, 
controller, thermal analyzer and operating software TA 60 from 
shimadzu corporation japan. The samples were placed in a sealed 
aluminum pan, before heating under nitrogen flow (30 ml/min) at a 
scanning rate of 5 °C/min from 25 °C to 250 °C. The heat flow as a 
function of temperature was measured for the drug and the former 
crystal mixture.  
XRPD studies 
This method is based on an interaction of a monochromatic X-ray 
beam with a crystalline substance. Different planes of atoms or 
molecules in a crystal act as a grating for X-rays. For monochromatic X-
rays, the diffraction angle solely depends on the crystalline spacings. 
The patterns provided by X-ray diffraction i.e. intensity vs. scattering 
angles is unique for each crystalline form of the compound. PXRD 
measurements were conducted using rigaku mini flex 600 X-ray 
diffractometer (Rigaku Co., Tokyo, Japan). The instrument was 
operated at 600 watts (X-ray tube), with a fixed tube current of 15 mA 
and a voltage of 40 kV. The diffracted X-ray beam was monochromated 
by a graphite monochromator and detected using standard 
scintillation counter. Diffraction intensities were measured by fixed 
time step scanning method in the range of 5-400 (2Ө). 
FTIR studies  
FTIR spectrum was generated for the prepared cocrystals using a 
Shimadzu FTIR-8300 spectrophotometer, and the spectrum was 
recorded in the region of 4000 to 400 cm-1. The procedure consisted 
of dispersing a sample (drug and cocrystals formers) in KBr and 
compressing into discs by applying a pressure of 5 tons for 5 min in 
a hydraulic press. The pellet was placed in the light path, and the 
spectrum was recorded for the all the batches of cocrystals. 
RESULTS AND DISCUSSION 
Solid state characterization of cocrystals 
Before cocrystals can be formulated into medicines, it is essential 
that their solid-state chemistry and stability is understood. It is also 
extremely useful to determine the crystal structure of the cocrystals, 
as this can provide significant new insights into how the drug and 
conformer interact, and thereby provide an excellent crystal 
engineering guide to new cocrystals, potentially with improved 
properties. Single-crystal X-ray diffraction will be used to determine 
their crystal structures; differential scanning calorimetry, X-ray 
powder diffraction (including variable-temperature), Raman 
spectroscopy (including again variable temperature) and hot-stage 
microscopy will be used to determine their stability and any phase 
transformations (including decomposition) which they might 
undergo as a function of temperature. 
The results indicate that peaks present in FTIR spectra of the drug 
are similar to peaks present in FTIR spectra of cocrystals of CCN-1 
with a marginal decrease in intensity and broadening of the peak at 
wave number 2994.00 cm-1 was observed due to the involvement of 
N-H hydrogen of secondary amide in intermolecular hydrogen 
bonding. This formation of hydrogen bonding is due to the 
involvement of N-H hydrogen of secondary amide in intermolecular 
hydrogen bonding. Thus the results of FTIR spectroscopy support 
the formation of intermolecular hydrogen bonding which are the 
characteristics of cocrystals, thus the results of FTIR spectroscopy 
support the formation of intermolecular hydrogen bonding which 
are the characteristics of cocrystals. (table no.2 and fig. no.3 and 4). 
 
Table 2: Major IR peaks (wavenumbers) and DSC thermograms results of cocrystals 
Batch No. Samples Composition Major peaks (Wave numbers, cm-1) (By FTIR) Melting points (By DSC) 
CCN-1 Paclitaxel: NAR 
CCN-1 
1:1 3416.05(N-H), 2360.95,1643.41(C=0),, 1246.06, 1070.53, 
707.90 
209.60 ° C 
 
 
Fig. 3: FTIR spectra of PTX 
 
The DSC thermograms of the pure drug showed a sharp 
endothermic peak at 223.00 °C. Paclitaxel cocrystals showed 
sharp endothermic @ 320.00 °C; the results indicate that 
intensity of endothermic peaks observed in cocrystals was 
slightly lesser and distinct, with a different melting transition 
from that observed with either of the individual components, 
resulting in the formation of new crystalline phase. (table 2: and 
fig. 5 and 6). 
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The pure drug and cocrystals are demonstrated by the diffraction 
patterns. The intensity of X-ray diffraction pattern for the pure drug, 
at a 2 Ө angle of 12.22 was found to be 100%. Whereas, cocrystals 
showed 100% intensity at 22.10 2 Ө angle. The shifting of 100% 
intensity for 2 Ө angle in comparison with pure and cocrystals is 
mainly because of interplanar distance (d angle) indicating the 
different arrangement of molecules, hence confirms the 
development of new crystalline phase. (table 3: and fig. 7 and 8). 
 
 
Fig. 4: FTIR spectra of PTX: NAR-CCN-1 
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Fig. 5: DSC Thermogram of PTX 
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Fig. 6: DSC Thermogram of PTX: NAR-CCN-1 
 
Table 3: PXRD data of cocrystals and paclitaxel 
Sample 2θ (deg) d (ang.) Intensity 
Paclitaxel 12.22 7.23 2487.74 
Paclitaxel: NAR(1:1) Co-crystal (CCN-1) 22.10 4.01 3121.08 
 
 
Fig. 7: PXRD of PTX 
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Fig. 8: PXRD of PTX: NAR-CCN-1 
 
Chemical stability 
The drug content of the optimized cocrystals CCN-1 was calculated 
using RP-HPLC technique and was found to be within and 
98.86±0.13 also the peak purity results shows that drug is stable, 
and no degradation peaks were interfering the results and with 
0.99988 of total peak purity index. The peak purity index of the 
paclitaxel was passed the criteria. Paclitaxel eluted at retention time 
of 4.80±0.032 min and total chromatographic run time was 7.00 min. 
(fig. no.09). 
Physical stability 
The optimized CCN-1 was found to be extremely stable after a 
maximum period of 90 d, at 25 ° and 40 °C which was confirmed by 
X-ray diffractogram and microscopic methods using stage and 
eyepiece micrometers to determine the change in the appearance of 
the cocrystals with respect to initial zero hour analysis. 
Solubility studies of prepared cocrystals 
From the results, it was observed that the batch CCN-1 shows 
statistically significant enhancement in the saturation solubilities as 
compared to their other batches and pure drug indicating the 
formation of cocrystals. (table 4:) 
 
 
Fig. 9: Peak purity curve for the cocrystals PTX: NAR-CCN-1 for 
proving chemical stability 
 
Table 4: Saturation solubility studies of cocrystals 
Sample (n=3) Solubility in ultra-clear water in µg ml-1±SD Solubility In pH 6.8 phosphate buffer in µg ml-1±SD 
Paclitaxel 1.34±0.25 µg ml-1 1.38±0.41 µg ml-1 
Paclitaxel: NAR(1:1) Co-crystal (CCN-1) 3.17±0.87 µg ml-1 3.22±0.65 µg ml-1 
Paclitaxel: NAR(1:2) Co-crystal (CCN-1) 2.14±0.28 µg ml-1 2.29±0.73 µg ml-1 
Paclitaxel: NAR(2:1) Co-crystal (CCN-1) 1.64±0.36 µg ml-1 1.76±0.12 µg ml-1 
 
CONCLUSION 
Paclitaxel cocrystals were prepared by solvent-assisted co-grinding 
method with the aim of increasing the solubility of the drug. Batches 
were made using naringen in different molar ratios.  
The most important conclusions of the present work can be 
summarized as:  
Paclitaxel was able to form stable cocrystals with Naringen in 
different ratios. The cocrystals formed were characterized and the 
analysis for saturation solubility and dissolution was carried out. 
Cocrystals of Paclitaxel: NAR in 1:1, 1:2 and 2:1 molar ratios were 
prepared by solvent-assisted co-grinding method. The formation 
of the cocrystals was confirmed by solid-state characterization of 
Paclitaxel: NAR(1:1) Co-crystal (CCN-1) batch based on the 
solubility studies which included PXRD, DSC and FTIR, the results 
of which proved the structural modifications in the cocrystal. 
PXRD results exhibited changes in the peak locations and patterns 
indicating the development of new crystalline phase. DSC 
thermogram showed the endothermic peaks at 223.00 °C for pure 
PTX, whereas endothermic peaks for cocrystals were observed at 
320.00 °C for cocrystals which support the above findings. These 
results were also supported by FTIR spectrum that confirmed the 
hydrogen bond formation. The cocrystals were found to be 
physically and chemically stable. A 2.4 fold increase in the 
saturation solubility of Paclitaxel: NAR(1:1) Co-crystal (CCN-1) 
was observed in its co-crystallized form. 
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